| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other expense, net | -8,317 | -53,801 | ||
| Income (loss) before income taxes and provision for income taxes | 24,325 | -71,790 | ||
| Provision for income taxes | 0 | 0 | ||
| Net income (loss) | 24,325 | -71,790 | ||
| Deemed dividend from series d redeemable convertible preferred stock (see note 6) | 0 | 384,436 | ||
| Adjustments of redeemable convertible preferred stock to redemption value | 0 | 60,971 | ||
| Net income (loss) attributable to common shareholders basic | 24,325 | -517,197 | ||
| Net income (loss) attributable to common shareholders diluted | 24,325 | -517,197 | ||
| Basic (in dollars per share) | 0.09 | -7.97 | ||
| Basic (in shares) | 282,099,073 | 64,918,988 | ||
| Diluted (in dollars per share) | 0.08 | -7.97 | ||
| Diluted (in shares) | 297,211,838 | 64,918,988 | ||
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)